Could Duration of Prostate Cancer Hormone Therapy Be Halved?

Preliminary research suggests it might be safe to shorten the current 3-year treatment

HealthDay + More

But the USPSTF stance is controversial, and Roth said these new findings highlight how complicated the issue is. He and Brawley said the study doesn't offer any solid answers, either. For one thing, the findings do not show whether having intermediate- or high-risk tumors diagnosed by PSA screening actually cut men's risk of dying from the cancer.

Brawley said he is in the camp that believes PSA screening should be done on a very limited basis.

Roth pointed to the recommendations of the American Society of Clinical Oncology (ASCO), which sponsored the meeting. ASCO suggests that doctors discuss PSA screening with men likely to live for at least 10 more years.

The reasoning is that elderly men in poor health are very unlikely to see any benefits from PSA screening.

"I don't think we can make a blanket recommendation for all men on PSA screening," Roth said.

More information

Learn more about prostate cancer from the American Cancer Society.

Copyright © 2012 HealthDay. All rights reserved.